Latest News
BCAC media release - 5 March 2020
It is fantastic news that funding for a vital drug for women with advanced breast cancer, palbociclib (Ibrance), will cover the costs for all those who need it , Libby Burgess, Chair of the Breast Cancer Aotearoa Coalition (BCAC) says.
A clinical trial shows that tucatinib, an investigative therapy used in combination with trastuzumab and capecitabine, reduces risk of death at two years by one-third in women with HER2-positive metastatic breast cancer (HER2+ MBC).
BCAC media release, 15 January 2020: Breast Cancer Aotearoa Coalition (BCAC) is delighted to hear that Ibrance (palbociclib) will be funded by PHARMAC from 1 April 2020.
BCAC would love you to show support for an intrepid couple who cycled from Dunedin to Parliament to garner support for a petition that would help improve the lives of women with breast cancer and people with other diseases.